Genius Sports Limited (NYSE: GENI) closed the day trading at $4.45 up 7.49% from the previous closing price of $4.14. In other words, the price has increased by $+0.3100 from its previous closing price. On the day, 1299556 shares were traded. GENI stock price reached its highest trading level at $4.6200 during the session, while it also had its lowest trading level at $4.1600.
For a better understanding of GENI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 1.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Credit Suisse on January 19, 2022, initiated with a Outperform rating and assigned the stock a target price of $15.
On November 24, 2021, The Benchmark Company reiterated its Buy rating and also upped its target price recommendation from $33 to $20.
On October 11, 2021, UBS started tracking the stock assigning a Neutral rating and target price of $18.UBS initiated its Neutral rating on October 11, 2021, with a $18 target price.
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.81 while its Price-to-Book (P/B) ratio in mrq is 1.56.
Stock Price History:
Over the past 52 weeks, GENI has reached a high of $7.09, while it has fallen to a 52-week low of $2.20. The 50-Day Moving Average of the stock is 4.2494, while the 200-Day Moving Average is calculated to be 3.7928.
Over the past 3-months, GENI traded about 886.79K shares per day on average, while over the past 10 days, GENI traded about 925.54k shares per day. A total of 200.14M shares are outstanding, with a floating share count of 112.61M. Insiders hold about 46.69% of the company’s shares, while institutions hold 35.20% stake in the company. Shares short for GENI as of Oct 13, 2022 were 4.91M with a Short Ratio of 5.07M, compared to 4.74M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 2.25% and a Short% of Float of 4.65%.
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.07 for the current quarter, with a high estimate of $0.03 and a low estimate of -$0.13, while EPS last year was -$0.37. The consensus estimate for the next quarter is -$0.09, with high estimates of $0.01 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.18 and -$0.51 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.25, with 6 analysts recommending between $0.19 and -$0.52.
A total of 8 analysts have provided revenue estimates for GENI’s current fiscal year. The highest revenue estimate was $342.4M, while the lowest revenue estimate was $334M, resulting in an average revenue estimate of $339.76M. In the same quarter a year ago, actual revenue was $262.74M, up 29.30% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $405.56M in the next fiscal year. The high estimate is $412.5M and the low estimate is $393M. The average revenue growth estimate for next year is up 19.40% from the average revenue estimate for this year.